Oyster Point Pharma to Present at the BIO CEO & Investor Conference

PRINCETON, New Jersey – January 24, 2019 – Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of Dry Eye Disease, today announced that Jeffrey Nau, M.M.S., Ph.D., President and CEO, is scheduled to present a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 12th, 2019 at 10:30 a.m. EST in New York.

About Oyster Point Pharma, Inc.

Oyster Point Pharma is a clinical-stage pharmaceutical company leveraging neuroscience to discover, develop, and commercialize novel therapies to treat diseases with high unmet needs. The company’s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease by stimulating the trigeminal parasympathetic pathway to activate the glands and cells responsible for tear film production, known as the Lacrimal Functional Unit. Oyster Point is leveraging a class of molecules called nicotinic acetylcholine receptor (nAChR) agonists to bind receptors on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production.

For more information visit https://oysterpointrx.com/ and follow on Twitter at @OysterPointRx.

Media contact:

Krysta Pellegrino
650-255-6142
Krysta@healthandcommerce.com